S&P 500   4,544.90 (-0.11%)
DOW   35,677.02 (+0.21%)
QQQ   374.10 (-0.84%)
AAPL   148.69 (-0.53%)
MSFT   309.16 (-0.51%)
FB   324.61 (-5.05%)
GOOGL   2,751.33 (-3.04%)
TSLA   909.68 (+1.75%)
AMZN   3,335.55 (-2.90%)
NVDA   227.26 (+0.15%)
BABA   177.70 (+0.16%)
NIO   38.88 (-2.73%)
CGC   13.38 (-4.70%)
GE   104.05 (+0.87%)
AMD   119.82 (+0.41%)
MU   67.51 (-1.65%)
T   25.49 (-1.05%)
F   16.28 (-1.63%)
ACB   7.07 (-4.07%)
DIS   169.42 (-1.12%)
PFE   43.16 (+0.70%)
BA   212.97 (-0.64%)
AMC   36.60 (-6.73%)
S&P 500   4,544.90 (-0.11%)
DOW   35,677.02 (+0.21%)
QQQ   374.10 (-0.84%)
AAPL   148.69 (-0.53%)
MSFT   309.16 (-0.51%)
FB   324.61 (-5.05%)
GOOGL   2,751.33 (-3.04%)
TSLA   909.68 (+1.75%)
AMZN   3,335.55 (-2.90%)
NVDA   227.26 (+0.15%)
BABA   177.70 (+0.16%)
NIO   38.88 (-2.73%)
CGC   13.38 (-4.70%)
GE   104.05 (+0.87%)
AMD   119.82 (+0.41%)
MU   67.51 (-1.65%)
T   25.49 (-1.05%)
F   16.28 (-1.63%)
ACB   7.07 (-4.07%)
DIS   169.42 (-1.12%)
PFE   43.16 (+0.70%)
BA   212.97 (-0.64%)
AMC   36.60 (-6.73%)
S&P 500   4,544.90 (-0.11%)
DOW   35,677.02 (+0.21%)
QQQ   374.10 (-0.84%)
AAPL   148.69 (-0.53%)
MSFT   309.16 (-0.51%)
FB   324.61 (-5.05%)
GOOGL   2,751.33 (-3.04%)
TSLA   909.68 (+1.75%)
AMZN   3,335.55 (-2.90%)
NVDA   227.26 (+0.15%)
BABA   177.70 (+0.16%)
NIO   38.88 (-2.73%)
CGC   13.38 (-4.70%)
GE   104.05 (+0.87%)
AMD   119.82 (+0.41%)
MU   67.51 (-1.65%)
T   25.49 (-1.05%)
F   16.28 (-1.63%)
ACB   7.07 (-4.07%)
DIS   169.42 (-1.12%)
PFE   43.16 (+0.70%)
BA   212.97 (-0.64%)
AMC   36.60 (-6.73%)
S&P 500   4,544.90 (-0.11%)
DOW   35,677.02 (+0.21%)
QQQ   374.10 (-0.84%)
AAPL   148.69 (-0.53%)
MSFT   309.16 (-0.51%)
FB   324.61 (-5.05%)
GOOGL   2,751.33 (-3.04%)
TSLA   909.68 (+1.75%)
AMZN   3,335.55 (-2.90%)
NVDA   227.26 (+0.15%)
BABA   177.70 (+0.16%)
NIO   38.88 (-2.73%)
CGC   13.38 (-4.70%)
GE   104.05 (+0.87%)
AMD   119.82 (+0.41%)
MU   67.51 (-1.65%)
T   25.49 (-1.05%)
F   16.28 (-1.63%)
ACB   7.07 (-4.07%)
DIS   169.42 (-1.12%)
PFE   43.16 (+0.70%)
BA   212.97 (-0.64%)
AMC   36.60 (-6.73%)
NASDAQ:CHEK

Check-Cap Stock Forecast, Price & News

$0.89
-0.04 (-4.30 %)
(As of 10/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.87
$0.92
50-Day Range
$0.82
$1.12
52-Week Range
$0.24
$4.49
Volume788,511 shs
Average Volume9.39 million shs
Market Capitalization$41.18 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.22
30 days | 90 days | 365 days | Advanced Chart
Receive CHEK News and Ratings via Email

Sign-up to receive the latest news and ratings for Check-Cap and its competitors with MarketBeat's FREE daily newsletter.


Check-Cap logo

About Check-Cap

Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule system for colorectal cancer screening. Its patented technology, C-Scan, is a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer. The company was founded by Yoav Kimchy in 2005 and is headquartered in Isfiya, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
X-ray apparatus & tubes
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CHEK
Employees
65
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.35 per share

Profitability

Net Income
$-13.85 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$41.18 million
Next Earnings Date
11/17/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.73 out of 5 stars

Medical Sector

861st out of 1,358 stocks

X-Ray Apparatus & Tubes Industry

3rd out of 6 stocks

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Check-Cap (NASDAQ:CHEK) Frequently Asked Questions

Is Check-Cap a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Check-Cap in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Check-Cap stock.
View analyst ratings for Check-Cap
or view top-rated stocks.

What stocks does MarketBeat like better than Check-Cap?

Wall Street analysts have given Check-Cap a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Check-Cap wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Check-Cap's next earnings date?

Check-Cap is scheduled to release its next quarterly earnings announcement on Wednesday, November 17th 2021.
View our earnings forecast for Check-Cap
.

How were Check-Cap's earnings last quarter?

Check-Cap Ltd. (NASDAQ:CHEK) announced its quarterly earnings results on Thursday, August, 5th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01.
View Check-Cap's earnings history
.

How has Check-Cap's stock been impacted by COVID-19?

Check-Cap's stock was trading at $1.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CHEK stock has decreased by 32.5% and is now trading at $0.8905.
View which stocks have been most impacted by COVID-19
.

When did Check-Cap's stock split? How did Check-Cap's stock split work?

Check-Cap shares reverse split before market open on Wednesday, April 4th 2018. The 1-12 reverse split was announced on Wednesday, April 4th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 3rd 2018. An investor that had 100 shares of Check-Cap stock prior to the reverse split would have 8 shares after the split.

What price target have analysts set for CHEK?

2 brokerages have issued 1 year price targets for Check-Cap's stock. Their forecasts range from $2.00 to $3.00. On average, they anticipate Check-Cap's stock price to reach $2.50 in the next year. This suggests a possible upside of 180.7% from the stock's current price.
View analysts' price targets for Check-Cap
or view top-rated stocks among Wall Street analysts.

Who are Check-Cap's key executives?

Check-Cap's management team includes the following people:
  • Alex Ovadia, Chief Executive Officer
  • Joshua Belkar, Vice President-Operations
  • Mira Rosenzweig, Chief Financial Officer
  • Yoav Kimchy, Chief Technology Officer
  • Boaz Shpigelman, Vice President-Research & Development

Who are some of Check-Cap's key competitors?

What other stocks do shareholders of Check-Cap own?

When did Check-Cap IPO?

(CHEK) raised $13 million in an initial public offering on Thursday, February 19th 2015. The company issued 1,200,000 shares at a price of $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group served as the underwriters for the IPO and Feltl and Company was co-manager.

What is Check-Cap's stock symbol?

Check-Cap trades on the NASDAQ under the ticker symbol "CHEK."

How do I buy shares of Check-Cap?

Shares of CHEK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Check-Cap's stock price today?

One share of CHEK stock can currently be purchased for approximately $0.89.

How much money does Check-Cap make?

Check-Cap has a market capitalization of $41.18 million. The medical research company earns $-13.85 million in net income (profit) each year or ($0.08) on an earnings per share basis.

How many employees does Check-Cap have?

Check-Cap employs 65 workers across the globe.

What is Check-Cap's official website?

The official website for Check-Cap is www.check-cap.com.

Where are Check-Cap's headquarters?

How can I contact Check-Cap?

Check-Cap's mailing address is 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000. The medical research company can be reached via phone at 972546706451 or via email at [email protected].


This page was last updated on 10/22/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.